Home › Arrhythmia › NCT05935007

Aveir DR Real-World Evidence Post-Approval Study

Aveir Dual-Chamber Leadless Pacemaker Real-World Evidence Post-Approval Study

Who can join

Ages 18 and older · All sexes

Eligibility Criteria:

* Implanted with an Aveir DR leadless pacemaker
* Continuous enrollment in Medicare Part A and Part B for 12 months prior to implant and for -30 days after implant, except in the case of death within the 30-day period
* Ability to link with Medicare fee-for-service data

About the study

The purpose of this post-approval study is to evaluate the long-term safety of the dual-chamber Aveir DR leadless pacemaker using real-world evidence methods.

What is being tested

• Aveir DR Leadless Pacemaker System (device)

Sponsor: Abbott Medical Devices · Participants: 1,805 · Started: Oct 31, 2023

Contact the study team

• Nicole Harbert · Phone: 972-526-4841
• Stephanie Delgado · Phone: 818-493-3285

Official record on ClinicalTrials.gov — NCT05935007

Locations in the U.S.

Conditions

• Arrhythmia
• Bradycardia
• Atrioventricular Block

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.